Your browser doesn't support javascript.
loading
Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report.
Wang, Huaiyu; Fan, Zaiwen; Yang, Xiaoming; Wu, Qing; Jiang, Suxin; Zhu, Jingna; Liu, Jie; Zhou, Chuanhong; Liu, Yinghui; You, Xia; Han, Yong.
Affiliation
  • Wang H; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Fan Z; Medical Oncology Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Yang X; Anesthesiology Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Wu Q; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Jiang S; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Zhu J; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Liu J; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Zhou C; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Liu Y; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • You X; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, Jiangsu Province, People's Republic of China.
  • Han Y; Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Oncologist ; 29(6): 543-545, 2024 Jun 03.
Article in En | MEDLINE | ID: mdl-38204337
ABSTRACT
Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / ErbB Receptors / Lung Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / ErbB Receptors / Lung Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2024 Type: Article